stockrowAscendis Pharma A/S (ASND) vs Halozyme Therapeutics, Inc. (HALO)
- Ascendis Pharma A/S ASND 255.84 +0.94%
- Halozyme Therapeutics, Inc. HALO 104.38 −15.11%
Ascendis Pharma A/S and Halozyme Therapeutics, Inc. are both Biotechnology companies. Ascendis Pharma A/S is the larger, with a market value of $16.6B against $14.0B — 1.2× the size. Ascendis Pharma A/S trades at the lower P/E: 18.3× against 29.5×. Ascendis Pharma A/S grew revenue faster over the last twelve months: 126.0% against 45.0%. Ascendis Pharma A/S has the higher net margin (71.2% vs 26.9%) and the lower return on invested capital (15.1% vs 19.9%). Across the 21 metrics below, Halozyme Therapeutics, Inc. leads on 12 and Ascendis Pharma A/S on 9.
Valuation
Profitability
| Metric | ASND | HALO | Biotechnology median |
|---|---|---|---|
| Gross margin | 91.26% | 82.27% | 65.16% |
| Operating margin | 24.84% | 37.41% | 0.00% |
| Net margin | 71.20% | 26.93% | 0.00% |
| Free cash flow margin | 31.97% | 49.84% | 0.00% |
| Return on equity | 118.44% | 216.38% | (50.12%) |
| Return on assets | 44.34% | 17.05% | (45.60%) |
| Return on invested capital | 15.07% | 19.87% | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack